---
schema_version: "secwatch.filing_event.v1"
accession: "0000014272-24-000145"
form_type: "8-K"
ticker: "BMY"
cik: "0000014272"
company_name: "BRISTOL MYERS SQUIBB CO"
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:22:06.964285+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bristol Myers Q3 2024 revenue $11.9B (+8% YoY); raises full-year guidance, Cobenfy approved

## Summary
- Q3 2024 revenues $11.9B, up 8% (+10% ex-FX); GAAP EPS $0.60, Non-GAAP EPS $1.80.
- Growth Portfolio revenues $5.8B, up 18% (+20% ex-FX).
- U.S. approval of Cobenfy (schizophrenia) achieved in Q3.
- Raising 2024 revenue guidance to ~+5% (+6% ex-FX); Non-GAAP EPS range raised to $0.75–$0.95.
- Net impact of acquired IPRD charges and licensing income reduced EPS by $0.09 on both GAAP and Non-GAAP.

## SEC filing metadata
- accession: 0000014272-24-000145
- form_type: 8-K
- ticker: BMY
- cik: 0000014272
- company_name: BRISTOL MYERS SQUIBB CO
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/14272/000001427224000145/0000014272-24-000145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/14272/000001427224000145/bmy-20241031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000014272-24-000145
- JSON: https://secwatch.observer/filing/0000014272-24-000145.json
- Plain text: https://secwatch.observer/filing/0000014272-24-000145.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.